MiRNA in melanoma-derived exosomes

Cancer Letters

Volumn 347, Issue 1, 2014, Pages 29-37

  Gajos Michniewicz, Anna ^a   Duechler, Markus ^b   Czyz, Malgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

Author keywords

Biomarker; Exosome; Melanoma; MicroRNA; MiRNA

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 221; MICRORNA 222; MICRORNA 31;

3' UNTRANSLATED REGION; BIOCHEMICAL COMPOSITION; BIOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER MORTALITY; CELL PROLIFERATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; EPIGENETICS; EXOSOME; GENE EXPRESSION REGULATION; HUMAN; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RNA DEGRADATION; SHORT SURVEY; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT;

BIOMARKER; EXOSOME; MELANOMA; MICRORNA; MIRNA;

EXOSOMES; HUMANS; MELANOMA; MICRORNAS;

EID: 84897046745     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.004     Document Type: Review

References (135)

1. Trams E.G., Lauter C.J., Salem N., Heine U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim. Biophys. Acta 1981, 645:63-70.
2. Denzer K., Kleijmeer M.J., Heijnen H.F., Stoorvogel W., Geuze H.J. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J. Cell Sci. 2000, 113:3365-3374.
3. Vlassov A.V., Magdaleno S., Setterquist R., Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta 1820, 2012:940-948.
4. Yang C., Robbins P.D. The roles of tumor-derived exosomes in cancer pathogenesis. Clin. Dev. Immunol. 2011, 2011:842-849.
5. Hannafon B.N., Ding W.Q. Intercellular communication by exosome-derived microRNAs in cancer. Int. J. Mol. Sci. 2013, 14:14240-14269.
6. Taylor D.D., Gercel-Taylor C. The origin, function, and diagnostic potential of RNA within extracellular vesicles present in human biological fluids. Front. Genet. 2013, 4:142.
7. Subra C., Grand D., Laulagnier K., Stella A., Lambeau G., Paillasse M., de Medina P., Monsarrat B., Perret B., Silvente-Poirot S., Poirot M., Record M. Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J. Lipid Res. 2010, 51:2105-2120.
8. Trajkovic K., Hsu C., Chiantia S., Rajendran L., Wenzel D., Wieland F., Schwille P., Brugger B., Simons M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008, 319:1244-1247.
9. Conde-Vancells J., Rodriguez-Suarez E., Embade N., Gil D., Matthiesen R., Valle M., Elortza F., Lu S.C., Mato J.M., Falcon-Perez J.M. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J. Proteome Res. 2008, 7:5157-5166.
10. Azmi A.S., Bao B., Sarkar F.H. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013, 32:623-642.
11. Gross J.C., Chaudhary V., Bartscherer K., Boutros M. Active Wnt proteins are secreted on exosomes. Nat. Cell Biol. 2012, 14:1036-1045.
12. Gross J.C., Boutros M. Secretion and extracellular space travel of Wnt proteins. Curr. Opin. Genet. Dev. 2013, 23:385-390.
13. Hasegawa H., Thomas H.J., Schooley K., Born T.L. Native IL-32 is released from intestinal epithelial cells via a nonclassical secretory pathway as a membrane-associated protein. Cytokine 2011, 53:74-83.
14. Mears R., Craven R.A., Hanrahan S., Totty N., Upton C., Young S.L., Patel P., Selby P.J., Banks R.E. Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics 2004, 4:4019-4031.
15. Thomas S.N., Liao Z., Clark D., Chen Y., Samadani R., Mao L., Ann D.K., Baulch J.E., Shapiro P., Yang A.J. Exosomal proteome profiling: a potential multi-marker cellular phenotyping tool to characterize hypoxia-induced radiation resistance in breast cancer. Proteomes 2013, 1:87-108.
16. Théry C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2:569-579.
17. Clayton A., Turkes A., Dewitt S., Steadman R., Mason M.D., Hallett M.B. Adhesion and signaling by B cell-derived exosomes: the role of integrins. FASEB J. 2004, 18:977-979.
18. Ohshima K., Inoue K., Fujiwara A., Hatakeyama K., Kanto K., Watanabe Y., Muramatsu K., Fukuda Y., Ogura S., Yamaguchi K., Mochizuki T. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One 2010, 5:e13247.
19. Skog J., Würdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., Curry W.T., Carter B.S., Krichevsky A.M., Breakefield X.O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10:1470-1476.
20. Hessvik N.P., Phuyal S., Brech A., Sandvig K., Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim. Biophys. Acta 1819, 2012:1154-1163.
21. Villarroya-Beltri C., Gutiérrez-Vázquez C., Sánchez-Cabo F., Pérez-Hernández D., Vázquez J., Martin-Cofreces N., Martinez-Herrera D.J., Pascual-Montano A., Mittelbrunn M., Sánchez-Madrid F. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. Commun. 2013, 4:2980.
22. Bobrie A., Colombo M., Raposo G., Thery C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 2011, 12:1659-1668.
23. Simons M., Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 2009, 21:575-581.
24. Théry C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9:581-593.
25. Théry C. Exosomes: secreted vesicles and intercellular communications. Biol. Rep. 2011, 3:15.
26. Kosaka N., Iguchi H., Yoshioka Y., Takeshita F., Matsuki Y., Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 285:17442-17452.
27. Thompson C.A., Purushothaman A., Ramani V.C., Vlodavsky I., Sanderson R.D. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J. Biol. Chem. 2013, 288:10093-10099.
28. Yu X., Harris S.L., Levine A.J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006, 66:4795-4801.
29. Llorente A., van Deurs B., Sandvig K. Cholesterol regulates prostasome release from secretory lysosomes in PC-3 human prostate cancer cells. Eur. J. Cell Biol. 2007, 86:405-415.
30. Koumangoye R.B., Sakwe A.M., Goodwin J.S., Patel T., Ochieng J. Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading. PLoS One 2011, 6:e24234.
31. Parolini I., Federici C., Raggi C., Lugini L., Palleschi S., de Milito A., Coscia C., Iessi E., Logozzi M., Molinari A., Colone M., Tatti M., Sargiacomo M., Fais S. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 2009, 284:34211-34222.
32. King H.W., Michael M.Z., Gleadle J.M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012, 12:421.
33. Montecalvo A., Larregina A.T., Shufesky W.J., Stolz D.B., Sullivan M.L., Karlsson J.M., Baty C.J., Gibson G.A., Erdos G., Wang Z., Milosevic J., Tkacheva O.A., Divito S.J., Jordan R., Lyons-Weiler J., Watkins S.C., Morelli A.E. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012, 119:756-766.
34. Feng D., Zhao W.L., Ye Y.Y., Bai X.C., Liu R.Q., Chang L.F., Zhou Q., Sui S.F. Cellular internalization of exosomes occurs through phagocytosis. Traffic 2010, 11:675-687.
35. Kahlert C., Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J. Mol. Med. 2013, 91:431-437.
36. Pant S., Hilton H., Burczynski M.E. The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem. Pharmacol. 2012, 83:1484-1494.
37. Urbanelli L., Magini A., Buratta S., Brozzi A., Sagini K., Polchi A., Tancini B., Emiliani C. Signaling pathways in exosomes biogenesis. Secretion Fate, Genes 2013, 4:152-170.
38. Hurley J.H., Odorizzi G. Get on the exosome bus with ALIX. Nat. Cell Biol. 2012, 14:654-655.
39. Wendler F., Bota-Rabassedas N., Franch-Marro X. Cancer becomes wasteful: emerging roles of exosomes (†) in cell-fate determination. J. Extracell. Vesicles 2013, 2:22390.
40. Kosaka N., Iguchi H., Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101:2087-2092.
41. Huang X., Yuan T., Tschannen M., Sun Z., Jacob H., Du M., Liang M., Dittmar R.L., Liu Y., Liang M., Kohli M., Thibodeau S.N., Boardman L., Wang L. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 2013, 14:319.
42. Camussi G., Deregibus M.C., Bruno S., Grange C., Fonsato V., Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am. J. Cancer Res. 2011, 1:98-110.
43. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
44. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
45. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
46. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105:10513-10518.
47. Zimmerman A.L., Wu S. MicroRNAs, cancer and cancer stem cells. Cancer Lett. 2011, 300:10-19.
48. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
49. Davalos V., Esteller M. MicroRNAs and cancer epigenetics: a macrorevolution. Curr. Opin. Oncol. 2010, 22:35-45.
50. Fabbri M., Calore F., Paone A., Galli R., Calin G.A. Epigenetic regulation of miRNAs in cancer. Adv. Exp. Med. Biol. 2013, 754:137-148.
51. Levy C., Khaled M., Iliopoulos D., Janas M.M., Schubert S., Pinner S., Chen P.H., Li S., Fletcher A.L., Yokoyama S., Scott K.L., Garraway L.A., Song J.S., Granter S.R., Turley S.J., Fisher D.E., Novina C.D. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol. Cell 2010, 40:841-849.
52. Suzuki H., Maruyama R., Yamamoto E., Kai M. Epigenetic alteration and microRNAs dysregulation in cancer. Front. Genet. 2013, 4:258.
53. Mulrane L., McGee S.F., Gallagher W.M., O'Connor D.P. MiRNA dysregulation in breast cancer. Cancer Res. 2013, 73:6554-6562.
54. Gruber A.J., Zavolan M. Modulation of epigenetic regulators and cell fate decisions by miRNAs. Epigenomics 2013, 5:671-683.
55. Younger S.T., Corey D.R. Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucleic Acids Res. 2011, 39:5682-5691.
56. Zardo G., Ciolfi A., Vian L., Starnes L.M., Billi M., Racanicchi S., Maresca C., Fazi F., Travaglini L., Noguera N., Mancini M., Nanni M., Cimino G., Lo-Coco F., Grignani F., Nervi C. Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood 2012, 119:4034-4046.
57. Huang V., Place R.F., Portnoy V., Wang J., Qi Z., Jia Z., Yu A., Shuman M., Yu J., Li L.C. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res. 2012, 40:1695-1707.
58. Mo M.H., Chen L., Fu Y., Wang W., Fu S.W. Cell-free circulating miRNA biomarkers in cancer. J. Cancer 2012, 3:432-448.
59. Shen Q., Bae H.J., Eun J.W., Kim H.S., Park S.J., Shin W.C., Lee E.K., Park S., Park W.S., Lee J.Y., Nam S.W. MiR-101 functions as a tumor suppressor by directly targeting nemo-like kinase in liver cancer. Cancer Lett. 2013, [Epub ahead of print].
60. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., Mitchell P.S., Bennett C.F., Pogosova-Agadjanyan E.L., Stirewalt D.L., Tait J.F., Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA 2011, 108:5003-5008.
61. Lund E., Guttinger S., Calado A., Dahlberg J.E., Kutay U. Nuclear export of microRNA precursors. Science 2004, 303:95-98.
62. Stoorvogel W. Functional transfer of microRNA by exosomes. Blood 2012, 119:646-648.
63. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110:13-21.
64. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
65. Leal J.A., Lleonart M.E. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett. 2013, 338:174-183.
66. Lee R.C., Feinbaum R.L., Ambros V. The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
67. Brennecke J., Hipfner D.R., Stark A., Russell R.B., Cohen S.M. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 2003, 113:25-36.
68. Chen P.S., Su J.L., Hungn M.C. Dysregulation of microRNAs in cancer. J. Biomed. Sci. 2012, 19:90.
69. Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., Liang S., Naylor T.L., Barchetti A., Ward M.R., Yao G., Medina A., O'Brien-Jenkins A., Katsaros D., Hatzigeorgiou A., Gimotty P.A., Weber B.L., Coukos G. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA 2006, 103:9136-9141.
70. Lages E., Ipas H., Guttin A., Nesr H., Berger F., Issartel J.P. MicroRNAs: molecular features and role in cancer. Front. Biosci. (Landmark Ed) 2012, 17:2508-2540.
71. Bell R.E., Levy C. The three M's: melanomamicrophthalmia-associated transcription factor and microRNA. Pigment Cell Melanoma Res. 2011, 24:1088-1106.
72. Dar A.A., Majid S., Rittsteuer C., de Semir D., Bezrookove V., Tong S., Nosrati M., Sagebiel R., Miller J.R., Kashani-Sabet M. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J. Natl. Cancer Inst. 2013, 105:433-442.
73. Mazar J., DeBlasio D., Govindarajan S.S., Zhang S., Perera R.J. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett. 2011, 585:2467-2476.
74. Davalos V., Moutinho C., Villanueva A., Boque R., Silva P., Carneiro F., Esteller M. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012, 31:2062-2074.
75. Gregory P.A., Bracken C.P., Smith E., Bert A.G., Wright J.A., Roslan S., Morris M., Wyatt L., Farshid G., Lim Y.Y., Lindeman G.J., Shannon M.F., Drew P.A., Khew-Goodall Y., Goodall G.J. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell 2011, 22:1686-1698.
76. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
77. Shi L., Jackstadt R., Siemens H., Li H., Kirchner T., Hermeking H. P53-Induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res. 2014, 74:532-542.
78. Chen P.S., Su J.L., Cha S.T., Tarn W.Y., Wang M.Y., Hsu H.C., Lin M.T., Chu C.Y., Hua K.T., Chen C.N., Kuo T.C., Chang K.J., Hsiao M., Chang Y.W., Chen J.S., Yang P.C., Kuo M.L. MiR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J. Clin. Invest. 2011, 121:3442-3455.
79. Zhuang G., Wu X., Jiang Z., Kasman I., Yao J., Guan Y., Oeh J., Modrusan Z., Bais C., Sampath D., Ferrara N. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012, 31:3513-3523.
80. Fabbri M., Paone A., Calore F., Galli R., Gaudio E., Santhanam R., Lovat F., Fadda P., Mao C., Nuovo G.J., Zanesi N., Crawford M., Ozer G.H., Wernicke D., Alder H., Caligiuri M.A., Nana-Sinkam P., Perrotti D., Croce C.M. MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA 2012, 109:E2110-E2116.
81. Jung T., Castellana D., Klingbeil P., Cuesta Hernández I., Vitacolonna M., Orlicky D.J., Roffler S.R., Brodt P., Zöller M. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 2009, 11:1093-1105.
82. Peinado H., Alečković M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., Hergueta-Redondo M., Williams C., García-Santos G., Nitadori-Hoshino A., Hoffman C., Badal K., Garcia B.A., Callahan M.K., Yuan J., Martins V.R., Skog J., Kaplan R.N., Brady M.S., Wolchok J.D., Chapman P.B., Kang Y., Bromberg J., Lyden D. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
83. Rana S., Malinowska K., Zöller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013, 15:281-295.
84. Hood J.L., San R.S., Wickline S.A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011, 71:3792-3801.
85. Dai S., Zhou X., Wang B., Wang Q., Fu Y., Chen T., Wan T., Yu Y., Cao X. Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. J. Mol. Med. (Berl) 2006, 84:1067-1076.
86. Elsner L., Muppala V., Gehrmann M., Lozano J., Malzahn D., Bickeböller H., Brunner E., Zientkowska M., Herrmann T., Walter L., Alves F., Multhoff G., Dressel R. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J. Immunol. 2007, 179:5523-5533.
87. Greenberg E.S., Chong K.K., Huynh K.T., Tanaka R., Hoon D.S. Epigenetic biomarkers in skin cancer. Cancer Lett. 2014, 342:170-177.
88. Kunz M. Oncogenes in melanoma: an update. Eur. J. Cell Biol. 2014, http://dx.doi.org/10.1016/j.ejcb.2013.12.002
89. Segura M.F., Greenwald H.S., Hanniford D., Osman I., Hernando E. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis 2012, 33:1823-1832.
90. Kappelmann M., Kuphal S., Meister G., Vardimon L., Bosserhoff A.K. MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene 2013, 32:2984-2991.
91. Greenberg E., Hershkovitz L., Itzhaki O., Hajdu S., Nemlich Y., Ortenberg R., Gefen N., Edry L., Modai S., Keisari Y., Besser M.J., Schachter J., Shomron N., Markel G. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 2011, 6:e18936.
92. Xiao D., Ohlendorf J., Chen Y., Taylor D.D., Rai S.N., Waigel S., Zacharias W., Hao H., McMasters K.M. Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One 2012, 7:e46874.
93. Müller D.W., Bosserhoff A.K. Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 2008, 27:6698-6706.
94. Schultz J., Lorenz P., Gross G., Ibrahim S., Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008, 18:549-557.
95. Bonazzi V.F., Stark M.S., Hayward N.K. MicroRNA regulation of melanoma progression. Melanoma Res. 2012, 22:101-113.
96. Luo C., Merz P.R., Chen Y., Dickes E., Pscherer A., Schadendorf D., Eichmüller S.B. MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett. 2013, 341:240-247.
97. Segura M.F., Hanniford D., Menendez S., Reavie L., Zou X., Alvarez-Diaz S., Zakrzewski J., Blochin E., Rose A., Bogunovic D., Polsky D., Wei J., Lee P., Belitskaya-Levy I., Bhardwaj N., Osman I., Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. USA 2009, 106:1814-1819.
98. Mattia G., Errico M.C., Felicetti F., Petrini M., Bottero L., Tomasello L., Romania P., Boe A., Segnalini P., Di Virgilio A., Colombo M.P., Carè A. Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma. Pigment Cell Melanoma Res. 2011, 24:953-965.
99. Felicetti F., Errico M.C., Segnalini P., Mattia G., Carè A. MicroRNA-221 and -222 pathway controls melanoma progression. Expert. Rev. Anticancer Ther. 2008, 8:1759-1765.
100. Igoucheva O., Alexeev V. MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem. Biophys. Res. Commun. 2009, 379:790-794.
101. Asangani I.A., Harms P.W., Dodson L., Pandhi M., Kunju L.P., Maher C.A., Fullen D.R., Johnson T.M., Giordano T.J., Palanisamy N., Chinnaiyan A.M. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012, 3:1011-1025.
102. Mueller D.W., Rehli M., Bosserhoff A.K. MiRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J. Invest. Dermatol. 2009, 129:1740-1751.
103. Satzger I., Mattern A., Kuettler U., Weinspach D., Niebuhr M., Kapp A., Gutzmer R. MicroRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. Exp. Dermatol. 2012, 21:509-514.
104. Shull A.Y., Latham-Schwark A., Ramasamy P., Leskoske K., Oroian D., Birtwistle M.R., Buckhaults P.J. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 2012, 7:e43369.
105. Satzger I., Mattern A., Kuettler U., Weinspach D., Voelker B., Kapp A., Gutzmer R. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer. 2010, 126:2553-2562.
106. Bar-Eli M. Searching for the 'melano-miRs': miR-214 drives melanoma metastasis. EMBO J. 2011, 30:1880-1881.
107. Penna E., Orso F., Cimino D., Tenaglia E., Lembo A., Quaglino E., Poliseno L., Haimovic A., Osella-Abate S., De Pittà C., Pinatel E., Stadler M.B., Provero P., Bernengo M.G., Osman I., Taverna D. MicroRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 2011, 30:1990-2007.
108. Gaziel-Sovran A., Segura M.F., Di Micco R., Collins M.K., Hanniford D., Vega-Saenz De Miera E., Rakus J.F., Dankert J.F., Shang S., Kerbel R.S., Bhardwaj N., Shao Y., Darvishian F., Zavadil J., Erlebacher A., Mahal L.K., Osman I., Hernando E. MiR-30b/30 degrulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011, 20:104-118.
109. Kitago M., Martinez S.R., Nakamura T., Sim M.S., Hoon D.S.B. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin. Cancer Res. 2009, 15:2988-2994.
110. Glud M., Rossing M., Hother C., Holst L., Hastrup N., Nielsen F.C., Gniadecki R., Drzewiecki K.T. Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res. 2010, 20:479-484.
111. Haflidadóttir B.S., Bergsteinsdóttir K., Praetorius C., Steingrímsson E. MiR-148 regulates Mitf in melanoma cells. PLoS One 2010, 5:e11574.
112. Mazar J., DeYoung K., Khaitan D., Meister E., Almodovar A., Goydos J., Ray A., Perera R.J. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One 2010, 5:e13779.
113. Chen J., Feilotter H.E., Pare G.C., Zhang X., Pemberton J.G., Garady C., Lai D., Yang X., Tron V.A. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am. J. Pathol. 2010, 176:2520-2529.
114. Braig S., Mueller D., Rothhammer T., Bosserhoff A.K. MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. Cell Mol. Life Sci. 2010, 3535-3548.
115. Adam L., Zhong M., Choi W., Qi W., Nicoloso M., Arora A., Calin G., Wang H., Siefker-Radtke A., McConkey D., Bar-Eli M., Dinney C. MiR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15:5060-5072.
116. Elson-Schwab I., Lorentzen A., Marshall C.J. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS One 2010, 5:e13176.
117. Philippidou D., Schmitt M., Moser D., Margue C., Nazarov P.V., Muller A., Vallar L., Nashan D., Behrmann I., Kreis S. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010, 70:4163-4173.
118. Dar A.A., Majid S., de Semir D., Nosrati M., Bezrookove V., Kashani-Sabet M. MiRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J. Biol. Chem. 2011, 286:16606-16614.
119. Shtam T.A., Kovalev R.A., Varfolomeeva E.Y., Makarov E.M., Kil Y.V., Filatov M.V. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun. Signal 2013, 11:88.
120. El Andaloussi S., Lakhal S., Mäger I., Wood M.J. Exosomes for targeted siRNA delivery across biological barriers. Adv. Drug Deliv. Rev. 2013, 65:391-397.
121. van Dommelen S.M., Vader P., Lakhal S., Kooijmans S.A., van Solinge W.W., Wood M.J., Schiffelers R.M. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J. Controlled Release 2012, 161:635-644.
122. van den Boorn J.G., Dassler J., Coch C., Schlee M., Hartmann G. Exosomes as nucleic acid nanocarriers. Adv. Drug Deliv. Rev. 2013, 65:331-335.
123. Kooijmans S.A., Vader P., van Dommelen S.M., van Solinge W.W., Schiffelers R.M. Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomedicine 2012, 7:1525-1541.
124. Tian X., Zhu M., Nie G. How can nanotechnology help membrane vesicle-based cancer immunotherapy development?. Hum. Vaccin. Immunother. 2013, 9:222-225.
125. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29:341-345.
126. Ruiss R., Jochum S., Mocikat R., Hammerschmidt W., Zeidler R. EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells - a new option for the treatment of B-CLL. PLoS One 2011, 6:e25294.
127. Ohno S., Takanashi M., Sudo K., Ueda S., Ishikawa A., Matsuyama N., Fujita K., Mizutani T., Ohgi T., Ochiya T., Gotoh N., Kuroda M. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 2013, 21:185-191.
128. Katakowski M., Buller B., Zheng X., Lu Y., Rogers T., Osobamiro O., Shu W., Jiang F., Chopp M. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013, 335:201-204.
129. Escudier B., Dorval T., Chaput N., André F., Caby M.P., Novault S., Flament C., Leboulaire C., Borg C., Amigorena S., Boccaccio C., Bonnerot C., Dhellin O., Movassagh M., Piperno S., Robert C., Serra V., Valente N., Le Pecq J.B., Spatz A., Lantz O., Tursz T., Angevin E., Zitvogel L. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J. Transl. Med. 2005, 3:10.
130. Duechler M. Vehicles for small interfering RNA transfection: exosomes versus synthetic nanocarriers. RNAN 2013, 1:16-26.
131. Yeo R.W., Lai R.C., Zhang B., Tan S.S., Yin Y., Teh B.J., Lim S.K. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 2013, 65:336-341.
132. Hass R., Otte A. Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment. Cell Commun. Signal 2012, 10:26.
133. Zhu W., Huang L., Li Y., Zhang X., Gu J., Yan Y., Xu X., Wang M., Qian H., Xu W. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 2012, 315:28-37.
134. Hu G., Drescher K.M., Chen X.M. Exosomal miRNAs: biological properties and therapeutic potential. Front. Genet. 2012, 3:56.
135. Rabinowits G., Gerçel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10:42-46.